Phase IIa Study of WBI-1001 Cream for Atopic Dermatitis

Inclusion Criteria: * AD diagnosis (based on Hanifin's criteria) presenting a minimum of 1% and a maximum of 10% body surface area (BSA) excluding face, groin, scalp and genital areas. * Disease severity index (EASI) of less than 12, Investigator's Global Assessment (IGA) of 2-3 at Day 0. * In good general health and free of any condition that might impair evaluation of AD. * Women of child bearing potential (WOCBP) had to have a negative a negative serum human-beta chorionic gonadotropin pregnancy test before randomization. WOCBP had to abstain from sex or they and their partners had to use adequate contraceptive precautions for the duration of the study. * Willing and able to comply with the protocol and attend all study visits. * Provide a written informed consent form prior to initiation of study procedures. Exclusion Criteria: * Had spontaneously improving or rapidly deteriorating AD. * Had AD lesions on only hands and/or feet. * Had skin diseases other than AD. * Had active allergic contact dermatitis or other non-atopic forms of dermatitis. * Had other concomitant medical condition that could put the patient at risk during the study. * Had a history of neurological/psychiatric disorders that could interfere with the patient's participation. * Had systemic immunomodulatory therapies within 12 weeks prior to the baseline visit. * Had prolonged exposure to natural or artificial ultraviolet radiation within 4 weeks of baseline visit. * Had phototherapy (including laser), photo-chemotherapy or systemic AD therapy within 4 weeks prior to baseline visit. * Had topical AD therapies in the areas to be treated within 2 weeks prior to the baseline visit. * Had alcohol abuse in the last 2 years. * Had allergic history to any non-medical ingredients of the study cream. * Were treated with an investigational drug within 1 month of Day 0 or were currently participating in another trial.